
**2000:** ASMQ is first-line treatment

**2002:** Private sector social marketing of ACT & mRDT

**2004:** Village Malaria Worker (VMW) pilot

**2009:** MoH bans artemisinin monotherapies

**2010:** DHA PPQ is first-line treatment

**2011:** Eurartesim (DHA PPQ) receives Stringent Regulatory Approval

**2011:** Increased private sector regulation through public private partnership program

**2015:** ASMQ is first-line treatment in areas with treatment failure

#### 652 (2009); 1,001 (2011); 792 (2013); 858 (2015) = N. of ANTIMALARIAL-STOCKING OUTLETS

**Proportion of outlets with DHA PPQ in stock:**

Most antimalarial-stocking outlets had the first-line treatment in stock in 2015.

**Proportion of outlets stocking a malaria rapid diagnostic test (mRDT):**

Availability of mRDT increases over time.

**Market composition:**

70% of the market composition was comprised of drug stores, general retailers, & itinerant drug vendors in 2009, compared to 20% in 2015.

In 2009, 20% of the private sector were stocking oral artemisinin monotherapy, but **in 2015, only 1 product was found.**

**Antimalarial market share:**

In 2015, most of the antimalarials distributed were first-line ACT.